Biomea Fusion, Inc. (BMEA)

$12.07

+0.67 (+5.88%)
Rating:
Recommendation:
-
Symbol BMEA
Price $12.07
Beta 0.000
Volume Avg. 0.22M
Market Cap 352.066M
Shares () -
52 Week Range 2.84-16.28
1y Target Est -
DCF Unlevered BMEA DCF ->
DCF Levered BMEA LDCF ->
ROE -42.85% Strong Sell
ROA -45.14% Strong Sell
Operating Margin -
Debt / Equity 6.13% Neutral
P/E -
P/B 2.13 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BMEA news


Mr. Thomas Butler
Healthcare
Biotechnology
NASDAQ Global Select

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.